The global biologics contract manufacturing market size is expected to reach USD 34.7 billion by 2030, registering a CAGR of 10.5% over the forecast period. The global market was growing efficiently during the COVID-19 pandemic. This is due to a rise in R&D activities for the development of COVID-19 vaccines. In addition, there has been an expansion in manufacturing facilities to control the spread of the disease. For instance, in November 2021, Lonza announced that it has decided to expand its microbial development laboratories in Switzerland to support the company’s upcoming projects.
It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bylok™. The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.
Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.
It is believed that post-pandemic there will be numerous fundamental changes. There will be an increase in the production and manufacturing efforts for the development of vaccines and therapeutics against the coronavirus and a rise in digital capabilities across all their operating units. These initiatives will help them in joint planning with pharma clients in building more strategic partnerships. For instance, in January 2022, Lonza launched a technology that will be used for the discovery and design of antibodies that are biospecific and this technology will be called bylok™. The outsourcing of drugs or biologics manufacturing is rapidly increasing around the world.
Pharmaceutical and biotechnology companies concentrate on their core projects while reducing the operational costs associated with manufacturing drugs or biologics. Contract Manufacturing Organizations (CMOs) are specialized and experienced in conducting the entire process of manufacturing. In-house manufacturing of biologics is difficult as it is a complex process and involves many resources. CMOs link the demand and supply gap by focusing on improving the drug discovery process resulting in faster availability of biologics for patients. Hence, due to these factors, outsourcing activities are rapidly increasing.
Biologics Contract Manufacturing Market Report Highlights
- Based on products, the MABs segment accounted for the largest revenue share in 2021 as MABs are used in the treatment of a wide range of diseases, such as cancer, infectious diseases, asthma, and auto-immune diseases.
- Based on indications, the oncology segment dominated the market in 2021 with the largest revenue share. The main factor responsible for the high segment share is the increased number of cancer cases.
- North America dominated the global market in 2021 due to the increased outsourcing services for manufacturing drugs & biologics and high R&D expenditure in the region.
- The key players, such as Lonza, Wuxi Biologics, Thermo Fischer, are adopting rapid improvements in treatment and therapy as the primary focus to gain higher market shares.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Biologics Contract Manufacturing Market: Variables, Trends & Scope
Chapter 4 Biologics Contract Manufacturing Market: Product Segment Analysis
Chapter 5 Biologics Contract Manufacturing Market: Indication Segment Analysis
Chapter 6 : Biologics Contract Manufacturing Market Regional Analysis
Chapter 7 Competitive Analysis
Companies Mentioned
- Wuxi Biologics
- Abzena Ltd.
- Fujifilm Diosynth Biotechnologies
- Boehringer Ingelheim Bioxcellence
- Lonza
- Samsung Biologics
- Abbvie
- Catalent
- Bioreliance
- Se Thermo Fischer (Patheon)
- Eurofins Cdmo
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | April 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 15.67 Billion |
| Forecasted Market Value ( USD | $ 34.7 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
